Testing Data
(Purity Assessment by SDS-PAGE0.5 mug of Human Anti-C5 Antibody, MCA6103 (eculizumab biosimilar, research grade) was denatured and analyzed under reducing (R) and non-reducing (NR) conditions. Bands were visualized using Coomassie Blue staining. Full IgG (H2L2), heavy (H) and light chains (L) are indicated.)
C5 Monoclonal Antibody | anti-C5 antibody
Human Anti C5 (Eculizumab Biosimilar)
Human Anti-C5 Antibody is for research use only. It is suitable as a reference standard in a pharmacokinetic (PK) bridging ELISA with anti-eculizumab antibodies. It can also be used as capture and detection reagent in an anti-drug antibody (ADA) bridging ELISA, with an anti-eculizumab antibody in IgG1 format as reference standard.
Eculizumab (Soliris) is a humanized IgG2/4 kappa antibody. The heavy chains are comprised of human IgG2 sequences in CH1, the hinge and the adjacent portion CH2, and human IgG4 sequences in the remaining part of CH2 and CH3. The drug is used to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare acquired life-threatening disease of the blood characterized by destruction of red blood cells by the complement system. It also has approval as an orphan drug for treatment of atypical hemolytic uremic syndrome (aHUS). Eculizumab specifically binds to the terminal complement component 5 (C5) and inhibits the cleavage of C5 to C5a and C5b by the C5 convertase, which prevents the generation of the terminal complement complex C5b-9. Both C5a and C5b-9 cause the terminal complement-mediated events that are characteristic of PNH and aHUS. A 1:1 molar ratio of eculizumab to C5 is sufficient for C5 inhibition.
Testing Data
(Purity Assessment by SDS-PAGE0.5 mug of Human Anti-C5 Antibody, MCA6103 (eculizumab biosimilar, research grade) was denatured and analyzed under reducing (R) and non-reducing (NR) conditions. Bands were visualized using Coomassie Blue staining. Full IgG (H2L2), heavy (H) and light chains (L) are indicated.)
Testing Data
(Purity Assessment by SDS-PAGE0.5 mug of Human Anti-C5 Antibody, MCA6103 (eculizumab biosimilar, research grade) was denatured and analyzed under reducing (R) and non-reducing (NR) conditions. Bands were visualized using Coomassie Blue staining. Full IgG (H2L2), heavy (H) and light chains (L) are indicated.)
Testing Data
(Monodispersity assessment by HPLC-SECSize exclusion chromatography (SEC) of Human Anti-C5 Antibody, MCA6103 (eculizumab biosimilar, research grade) was performed on an analytical HPLC instrument. Shown is the monomer peak (H2L2), calculated relative monomer portion and aggregates. Column: MAbPac SEC-1, 5 mum; dimension: 4.0 x 150 mm; mobile phase: 50 mM sodium phosphate, pH 6.8, 300 mM NaCl, 200 mM Arginine; flow rate: 200 mul/min; inj. volume [mul]: 3; temp.: 25 degree C; detection: 280 nm; sample: mAb (1 mg/ml).)
Testing Data
(Monodispersity assessment by HPLC-SECSize exclusion chromatography (SEC) of Human Anti-C5 Antibody, MCA6103 (eculizumab biosimilar, research grade) was performed on an analytical HPLC instrument. Shown is the monomer peak (H2L2), calculated relative monomer portion and aggregates. Column: MAbPac SEC-1, 5 mum; dimension: 4.0 x 150 mm; mobile phase: 50 mM sodium phosphate, pH 6.8, 300 mM NaCl, 200 mM Arginine; flow rate: 200 mul/min; inj. volume [mul]: 3; temp.: 25 degree C; detection: 280 nm; sample: mAb (1 mg/ml).)
NCBI and Uniprot Product Information
NCBI Description
This gene encodes a component of the complement system, a part of the innate immune system that plays an important role in inflammation, host homeostasis, and host defense against pathogens. The encoded preproprotein is proteolytically processed to generate multiple protein products, including the C5 alpha chain, C5 beta chain, C5a anaphylatoxin and C5b. The C5 protein is comprised of the C5 alpha and beta chains, which are linked by a disulfide bridge. Cleavage of the alpha chain by a convertase enzyme results in the formation of the C5a anaphylatoxin, which possesses potent spasmogenic and chemotactic activity, and the C5b macromolecular cleavage product, a subunit of the membrane attack complex (MAC). Mutations in this gene cause complement component 5 deficiency, a disease characterized by recurrent bacterial infections. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Nov 2015]
Uniprot Description
C5: Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. Defects in C5 are the cause of complement component 5 deficiency (C5D). A rare defect of the complement classical pathway associated with susceptibility to severe recurrent infections, predominantly by Neisseria gonorrhoeae or Neisseria meningitidis. An association study of C5 haplotypes and genotypes in individuals with chronic hepatitis C virus infection shows that individuals homozygous for the C5_1 haplotype have a significantly higher stage of liver fibrosis than individuals carrying at least 1 other allele (PubMed:15995705).
Protein type: Secreted, signal peptide; Secreted
Chromosomal Location of Human Ortholog: 9q33-q34
Cellular Component: membrane attack complex; extracellular space; extracellular region
Molecular Function: protein binding; chemokine activity; endopeptidase inhibitor activity; receptor binding; C5a anaphylatoxin chemotactic receptor binding
Biological Process: activation of MAPK activity; positive regulation of chemotaxis; in utero embryonic development; cytolysis; complement activation, alternative pathway; chemotaxis; glucose homeostasis; leukocyte migration during inflammatory response; complement activation; cellular calcium ion homeostasis; G-protein coupled receptor protein signaling pathway; positive regulation of angiogenesis; cell surface receptor linked signal transduction; regulation of complement activation; response to stress; innate immune response; negative regulation of dopamine secretion; inflammatory response; complement activation, classical pathway
Disease: Complement Component 5 Deficiency; Eculizumab, Poor Response To
Research Articles on C5
Similar Products
Product Notes
The C5 c5 (Catalog #AAA225704) is an Antibody and is intended for research purposes only. The product is available for immediate purchase. AAA Biotech's C5 can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA). Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls. Researchers should empirically determine the suitability of the C5 c5 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "C5, Monoclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
